中智藥業(03737.HK)擬溢價約2.00%發行2360萬股 淨籌3605.54萬港元
格隆匯6月29日丨中智藥業(03737.HK)公吿,公司於2021年6月29日與諾偉其(為獨立第三方)訂立認購協議。根據認購協議,諾偉其已有條件同意認購且公司已有條件同意以認購價配發及發行合共2360萬股認購股份。
因此,根據認購協議發行的認購股份相當於公吿日期公司已發行股份總數的約2.81%及經配發及發行認購股份擴大已發行股份總數的約2.73%(假設於公吿日期後及於認購協議完成前已發行股份數目概無其他變動)。根據認購協議發行認購股份所得款項淨額(經扣除所有相關成及開支後)預計約為3605.54萬港元。
因此,每股股份淨價將約為1.53港元。每股認購股份認購價1.53港元較6月29日收市價每股1.500港元溢價約2.00%。認購股份將根據於股東周年大會上授予董事一般授權予以配發及發行。公司將向聯交所上市委員會申請批准認購股份上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.